Regeneron stock trades at 19.78 times earnings versus Vertex at 29.93

Published on 10/26/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron is valued at USD 82.3 billion, with 19.78 times earnings. Regeneron stock costs EUR 714.30 on October 26, 2026 at Lang & Schwarz.

Valuation and price facts

Regeneron trades at 19.78 times earnings versus Vertex at 29.93.
Regeneron's market capitalization was USD 82.3 billion on October 26, 2026.
Regeneron stock was at EUR 714.30 at Lang & Schwarz on October 26, 2026 at 5:46 p.m. CEST.

Regeneron, US75886F1075, Illustration mit AI erstellt.

Regeneron Pharmaceuticals (ISIN US75886F1075) trades at 19.78 times earnings, below Vertex Pharmaceuticals at 29.93 times. The valuation comparison gives investors a concrete reference ahead of Regeneron's next reported results. Regeneron was valued at USD 82.3 billion on October 26, 2026, while its Nasdaq quote stood at USD 799.42 at 12:51 p.m. ET. At Lang & Schwarz, the stock was at EUR 714.30 on October 26, 2026 at 5:46 p.m. CEST.

Why valuation matters before results

The earnings multiple places Regeneron below Vertex on the same market measure. Regeneron's multiple was 10.15 points lower, a difference of 34.00 percent relative to Vertex's 29.93 times earnings. The comparison describes valuation positioning rather than a forecast or recommendation.

Stock range remains wide

Regeneron's Nasdaq quote was USD 799.42 on October 26, 2026, compared with a 52-week range of USD 575.93 to USD 859.34. The stock therefore stood USD 59.92, or 6.98 percent, below its 52-week high. The same quote showed a market capitalization of USD 82.3 billion and trading volume of 151,949 shares.

Pipeline update and investor dates

Regeneron's investor materials list an October 16, 2026 update on Libtayo's recommendation for European Union approval under an updated dosing regimen. The company describes Libtayo as one of its marketed medicines, while its broader portfolio includes 16 medicines developed in-house and nearly 50 candidates in development, according to Regeneron.

Comparison with peers

Regeneron: down 0.70 percent on Nasdaq, 19.78 times earnings, market capitalization USD 82.3 billion.

Vertex Pharmaceuticals (Nasdaq, USD): down 1.82 percent, 29.93 times earnings, market capitalization USD 130.4 billion.

Gilead Sciences (Nasdaq, USD): up 1.56 percent, market capitalization USD 196.5 billion.

Price and valuation in view

The key distinction is the lower earnings multiple alongside a share price that remains within a broad 52-week range. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.